Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial

医学 放射治疗 临床终点 外科 肉瘤 随机对照试验 病理
作者
Sylvie Bonvalot,Alessandro Gronchi,C. Le Péchoux,Carol J. Swallow,D. Strauß,Pierre Méeus,Frits van Coevorden,Stephan Stoldt,Eberhard Stoeckle,Piotr Rutkowski,Marco Rastrelli,Chandrajit P. Raut,Daphne Hompes,Antonino De Paoli,Claudia Sangalli,Charles Honoré,Peter Chung,Aisha Miah,Jean‐Yves Blay,Marco Fiore,Jean‐Jacques Stelmes,Angelo Paolo Dei Tos,Elizabeth H. Baldini,Saskia Litière,Sandrine Marréaud,Hans Gelderblom,Rick L. Haas
出处
期刊:Lancet Oncology [Elsevier]
卷期号:21 (10): 1366-1377 被引量:329
标识
DOI:10.1016/s1470-2045(20)30446-0
摘要

Unlike for extremity sarcomas, the efficacy of radiotherapy for retroperitoneal sarcoma is not established. The aim of this study was to evaluate the impact of preoperative radiotherapy plus surgery versus surgery alone on abdominal recurrence-free survival.EORTC-62092 is an open-label, randomised, phase 3 study done in 31 research institutions, hospitals, and cancer centres in 13 countries in Europe and North America. Adults (aged ≥18 years) with histologically documented, localised, primary retroperitoneal sarcoma that was operable and suitable for radiotherapy, who had not been previously treated and had a WHO performance status and American Society of Anesthesiologists score of 2 or lower, were centrally randomly assigned (1:1), using an interactive web response system and a minimisation algorithm, to receive either surgery alone or preoperative radiotherapy followed by surgery. Randomisation was stratified by hospital and performance status. Radiotherapy was delivered as 50·4 Gy (in 28 daily fractions of 1·8 Gy) in either 3D conformal radiotherapy or intensity modulated radiotherapy, and the objective of surgery was a macroscopically complete resection of the tumour mass with en-bloc organ resection as necessary. The primary endpoint was abdominal recurrence-free survival, as assessed by the investigator, and was analysed in the intention-to-treat population. Safety was analysed in all patients who started their allocated treatment. This trial is registered with ClinicalTrials.gov, NCT01344018.Between Jan 18, 2012 and April 10, 2017, 266 patients were enrolled, of whom 133 were randomly assigned to each group. The median follow-up was 43·1 months (IQR 28·8-59·2). 128 (96%) patients from the surgery alone group had surgery, and 119 (89%) patients in the radiotherapy and surgery group had both radiotherapy and surgery. Median abdominal recurrence-free survival was 4·5 years (95% CI 3·9 to not estimable) in the radiotherapy plus surgery group and 5·0 years (3·4 to not estimable) in the surgery only group (hazard ratio 1·01, 95% CI 0·71-1·44; log rank p=0·95). The most common grade 3-4 adverse events were lymphopenia (98 [77%] of 127 patients in the radiotherapy plus surgery group vs one [1%] of 128 patients in the surgery alone group), anaemia (15 [12%] vs ten [8%]), and hypoalbuminaemia (15 [12%] vs five [4%]). Serious adverse events were reported in 30 (24%) of 127 patients in the radiotherapy plus surgery group, and in 13 (10%) of 128 patients in the surgery alone group. One (1%) of 127 patients in the radiotherapy plus surgery group died due to treatment-related serious adverse events (gastropleural fistula), and no patients in the surgery alone group died due to treatment-related serious adverse events.Preoperative radiotherapy should not be considered as standard of care treatment for retroperitoneal sarcoma.European Organisation for Research and Treatment of Cancer, and European Clinical Trials in Rare Sarcomas.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhangsudi发布了新的文献求助10
刚刚
隐形曼青应助小杨采纳,获得10
刚刚
刚刚
碧蓝丹烟发布了新的文献求助10
刚刚
Ran关闭了Ran文献求助
刚刚
1秒前
2秒前
WSY发布了新的文献求助10
2秒前
李浩然完成签到,获得积分10
3秒前
samgood完成签到,获得积分20
4秒前
漂亮的秋天完成签到,获得积分10
4秒前
damoq发布了新的文献求助30
4秒前
科研通AI2S应助小包包采纳,获得10
4秒前
4秒前
nite完成签到,获得积分10
4秒前
5秒前
所所应助要开心采纳,获得10
5秒前
5秒前
yingmo关注了科研通微信公众号
6秒前
6秒前
艺晨完成签到 ,获得积分10
7秒前
7秒前
linakg完成签到,获得积分10
9秒前
9秒前
秋半梦发布了新的文献求助10
10秒前
zhangsudi完成签到,获得积分10
10秒前
11秒前
12秒前
科目三应助不吃芹菜采纳,获得10
12秒前
dbb完成签到 ,获得积分10
12秒前
WSY完成签到,获得积分10
12秒前
13秒前
天天快乐应助ghghkhh采纳,获得30
14秒前
X_ye发布了新的文献求助10
14秒前
wanci应助bushuiniao采纳,获得10
15秒前
15秒前
余寻冬发布了新的文献求助10
18秒前
yingmo发布了新的文献求助10
18秒前
19秒前
愉快的牛氓完成签到,获得积分10
19秒前
高分求助中
求国内可以测试或购买Loschmidt cell(或相同原理器件)的机构信息 1000
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Sarcolestes leedsi Lydekker, an ankylosaurian dinosaur from the Middle Jurassic of England 500
Machine Learning for Polymer Informatics 500
《关于整治突出dupin问题的实施意见》(厅字〔2019〕52号) 500
2024 Medicinal Chemistry Reviews 480
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3218457
求助须知:如何正确求助?哪些是违规求助? 2867704
关于积分的说明 8157719
捐赠科研通 2534685
什么是DOI,文献DOI怎么找? 1367140
科研通“疑难数据库(出版商)”最低求助积分说明 644934
邀请新用户注册赠送积分活动 618123